Sermorelin is a synthetic peptide made of the first 29 amino acids of growth hormone-releasing hormone (GHRH), the hormone the hypothalamus uses to signal the pituitary gland to release growth hormone. It was once an FDA-approved prescription medicine sold under the brand name Geref. That product was discontinued, and today no FDA-approved sermorelin product is marketed in the United States.
Sermorelin acts one step earlier in the hormone chain than growth hormone itself. It is not growth hormone, and it is a different compound from newer GHRH analogs such as tesamorelin and CJC-1295.
Natural GHRH is 44 amino acids long, but its first 29 carry its full biological activity, and sermorelin copies that section. It binds to GHRH receptors on the pituitary gland, which respond by releasing growth hormone. Growth hormone then signals the liver and other tissues to make insulin-like growth factor 1 (IGF-1). Because the body's normal feedback controls stay in place, the response depends on a pituitary gland that can still make growth hormone.
The FDA approved two sermorelin products, both sold as Geref by Serono (later EMD Serono):
In 2008 EMD Serono told the FDA that both products were being discontinued and asked for the approvals to be withdrawn. The FDA withdrew both approvals effective June 18, 2009. In a 2013 Federal Register notice, the FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness, which means a generic version could be approved if it met all requirements. As of September 2026, the FDA's Drugs@FDA database lists no sermorelin product other than the discontinued Geref.
A 1999 review of the clinical data in the journal BioDrugs described sermorelin as a relatively specific diagnostic test for growth hormone deficiency when used alongside conventional tests. For children with idiopathic GHD, it found limited data showing faster growth over 12 months in some prepubertal children. Some sermorelin regimens produced smaller gains in growth rate than growth hormone (somatropin) itself, and the effect on final adult height had not been determined. The most commonly reported side effects were short-lived facial flushing and pain at the site where the drug was given.
Sermorelin was never approved as a therapy for adults, including for age-related declines in growth hormone. Those uses have not been established in large controlled trials.
Current status: Formerly FDA-approved (Geref, discontinued).
Because no approved sermorelin product is on the market, sermorelin offered today generally comes from compounding pharmacies, which prepare medicines for individual patients with a prescription. Compounded drugs are not FDA-approved, which means the FDA does not review them for safety, effectiveness or quality before they are sold. Sermorelin does not appear on the FDA's Category 2 list of bulk substances that raise significant safety concerns for compounding (as updated in April 2026).
Products labeled "for research purposes only" or "not for human consumption" are not approved medicines, and the FDA has not reviewed their contents.
The World Anti-Doping Agency (WADA) 2026 Prohibited List names sermorelin as a GHRH analog under class S2. It is prohibited at all times, in and out of competition.
Peptide Labs does not sell this compound. This page is general information, not medical advice. We are not a pharmacy, and we do not provide prescription medicines of any kind.
For personal medical questions, including questions about sermorelin, the right person to ask is a licensed healthcare provider.
See the full list of compound profiles in the Peptide Guide. For related compounds, see our profiles of tesamorelin and CJC-1295, or read whether peptides are legal in the U.S. For a side-by-side comparison, read tesamorelin vs sermorelin.